GlassScriptPhysician profile
Urvi R Patel
NPI 1952463648
$1,922.57
in general payments reported to CMS, 2019-2025
11 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $48.67 · 2021: $215 · 2022: $604 · 2023: $380 · 2024: $168 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $497.25 | 2023-2025 | Acuvue |
| Alcon Vision LLC | $304.67 | 2020-2025 | Total30, Precision 1 |
| Genentech USA, INC. | $256.97 | 2022 | |
| Glaukos Corporation | $214.98 | 2021-2023 | |
| Coopervision INC. | $147.55 | 2023-2024 | Onefit Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $132.60 | 2022-2023 | Infuse |
| Rxsight INC | $125.55 | 2025 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Allergan, INC. | $106.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $105.89 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Urvi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.